Blackham A and Griffiths RJ |
The effect of FK506 and cyclosporin A on antigen-induced arthritis. |
1991 |
Clin. Exp. Immunol. |
pmid:1718639
|
Ryu S and Yasunami Y |
Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. |
1991 |
Transplant. Proc. |
pmid:1703710
|
Alejandro R et al. |
Combined liver-islet allotransplantation in man under FK 506. |
1991 |
Transplant. Proc. |
pmid:1703712
|
Ito T et al. |
The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. |
1991 |
Transplant. Proc. |
pmid:1703716
|
Zheng B et al. |
Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. |
1991 |
Transplant. Proc. |
pmid:1703717
|
Yabuuchi H et al. |
Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. |
1991 |
Transplant. Proc. |
pmid:1703718
|
Iwasaki K et al. |
Pharmacokinetic study of FK 506 in the rat. |
1991 |
Transplant. Proc. |
pmid:1721268
|
Kay JE et al. |
Uptake of FK 506 by lymphocytes and erythrocytes. |
1991 |
Transplant. Proc. |
pmid:1721269
|
Jain AB et al. |
Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721270
|
Abu-Elmagd KM et al. |
Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1721271
|
Abu-Elmagd KM et al. |
Strategy of FK 506 therapy in liver transplant patients: effect of graft function. |
1991 |
Transplant. Proc. |
pmid:1721272
|
Ericzon BG et al. |
Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721273
|
Jain AB et al. |
Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. |
1991 |
Transplant. Proc. |
pmid:1721274
|
McMichael J et al. |
Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. |
1991 |
Transplant. Proc. |
pmid:1721275
|
Ali Shah I et al. |
Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. |
1991 |
Transplant. Proc. |
pmid:1721276
|
Rao P et al. |
Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. |
1991 |
Transplant. Proc. |
pmid:1721301
|
DiLella AG and Craig RJ |
Characterization of the human FKBP-12 gene and related pseudogenes. |
1991 |
Transplant. Proc. |
pmid:1721302
|
Kar S and Carr B |
Gene expression of FK 506-binding protein. |
1991 |
Transplant. Proc. |
pmid:1721303
|
Connelly PR |
Thermodynamics of interaction of FK 506-binding protein and its ligands. |
1991 |
Transplant. Proc. |
pmid:1721304
|
Donnelly JG and Soldin SJ |
Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. |
1991 |
Transplant. Proc. |
pmid:1721305
|
Rosborough SL et al. |
Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. |
1991 |
Transplant. Proc. |
pmid:1721306
|
Zeevi A et al. |
In vitro assessment of FK 506 immunosuppressive activity in transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721307
|
Katz HR et al. |
Mast cell biochemical and functional heterogeneity. |
1991 |
Transplant. Proc. |
pmid:1721308
|
Borg AJ and Kumagai M |
FK 506 and xenogeneic human anti-porcine cellular reactivity. |
1991 |
Transplant. Proc. |
pmid:1721332
|
Fung J et al. |
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. |
1991 |
Transplant. Proc. |
pmid:1721333
|
Winkler M et al. |
Use of FK 506 for treatment of chronic rejection after liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1721334
|
D'Alessandro AM et al. |
FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. |
1991 |
Transplant. Proc. |
pmid:1721335
|
Lewis WD et al. |
FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. |
1991 |
Transplant. Proc. |
pmid:1721336
|
Woodle ES et al. |
FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1721337
|
Shaw BW et al. |
FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. |
1991 |
Transplant. Proc. |
pmid:1721338
|
McDiarmid SV et al. |
FK 506 rescue therapy in liver transplantation: outcome and complications. |
1991 |
Transplant. Proc. |
pmid:1721339
|
Jordan ML et al. |
FK 506 conversion of renal allografts failing cyclosporine immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721365
|
Alessiani M et al. |
Infections in adult liver transplant patients under FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1703345
|
Offner G et al. |
FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. |
1991 |
Transplant. Proc. |
pmid:1721366
|
Imai K et al. |
Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1703347
|
|
Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. |
1991 |
Transplant. Proc. |
pmid:1721367
|
Starzl TE et al. |
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. |
1991 |
Transplant. Proc. |
pmid:1703351
|
Darras FS et al. |
Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721368
|
Shapiro R et al. |
Kidney transplantation under FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1703352
|
Todo S et al. |
Clinical small bowel or small bowel plus liver transplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1721369
|
Tzakis AG et al. |
Use of FK 506 in pediatric patients. |
1991 |
Transplant. Proc. |
pmid:1703353
|
Fries D et al. |
Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1721370
|
Jain AB et al. |
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1703354
|
Wijnen RM et al. |
Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. |
1991 |
Transplant. Proc. |
pmid:1721371
|
Venkataramanan R et al. |
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. |
1991 |
Transplant. Proc. |
pmid:1703355
|
Fung JJ et al. |
Adverse effects associated with the use of FK 506. |
1991 |
Transplant. Proc. |
pmid:1721372
|
Omar G et al. |
FK 506 inhibition of cyclosporine metabolism by human liver microsomes. |
1991 |
Transplant. Proc. |
pmid:1703356
|
Freise CE et al. |
Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. |
1991 |
Transplant. Proc. |
pmid:1721397
|
Eidelman BH et al. |
Neurologic complications of FK 506. |
1991 |
Transplant. Proc. |
pmid:1721398
|
Pelekanou V et al. |
FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. |
1991 |
Transplant. Proc. |
pmid:1721408
|
Tai J et al. |
In vivo and in vitro effect of FK 506 on rat Leydig cell function. |
1991 |
Transplant. Proc. |
pmid:1721409
|
Ricordi C et al. |
Human islet allotransplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1721410
|
Tze WJ et al. |
Long-term survival of islet allografts in diabetic rats treated with FK 506. |
1991 |
Transplant. Proc. |
pmid:1721411
|
Wang X et al. |
Intraportal FK 506 improves intrahepatic islet allograft survival. |
1991 |
Transplant. Proc. |
pmid:1721412
|
Ohtsuka S et al. |
The effect of short-term FK 506 therapy on pancreas transplantation in rats. |
1991 |
Transplant. Proc. |
pmid:1721413
|
Yamashita T et al. |
Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. |
1991 |
Transplant. Proc. |
pmid:1721414
|
Fukuzaki T et al. |
Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. |
1991 |
Transplant. Proc. |
pmid:1721415
|
Bierer BE et al. |
The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. |
1991 |
Eur. J. Immunol. |
pmid:1705513
|
Heitman J et al. |
FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. |
1991 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:1705713
|
Goebl MG |
The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. |
1991 |
Cell |
pmid:1706222
|
de Paulis A et al. |
FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. |
1991 |
J. Immunol. |
pmid:1706398
|
Griffiths EJ and Halestrap AP |
Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. |
1991 |
Biochem. J. |
pmid:1706598
|
Brabletz T et al. |
The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. |
1991 |
Nucleic Acids Res. |
pmid:1707162
|
Jiang H et al. |
Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. |
1991 |
Transplant. Proc. |
pmid:1721439
|
Sato K et al. |
Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. |
1991 |
Transplant. Proc. |
pmid:1721440
|
Katayama Y et al. |
Immunosuppressive effects of FK 506 in rat lung transplantation. |
1991 |
Transplant. Proc. |
pmid:1721441
|
Yokomise H et al. |
Immunosuppressive effects of FK 506 in canine lung transplantation. |
1991 |
Transplant. Proc. |
pmid:1721442
|
Hasegawa S et al. |
FK 506 and cyclosporine: effects and side effects in canine lung transplantation. |
1991 |
Transplant. Proc. |
pmid:1721443
|
Wada H et al. |
Dose response to FK 506 in canine lung transplantation. |
1991 |
Transplant. Proc. |
pmid:1721444
|
Lin CY et al. |
Effects of FK 506 on the biochemical markers in canine lung allograft rejection. |
1991 |
Transplant. Proc. |
pmid:1721445
|
Propper DJ et al. |
Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. |
1991 |
Transplant. Proc. |
pmid:1721446
|
Sigal NH et al. |
Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. |
1991 |
Transplant. Proc. |
pmid:1712132
|
Fung JJ et al. |
Current status of FK 506 in liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1712133
|
Francavilla A et al. |
Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. |
1991 |
Hepatology |
pmid:1712337
|
Aoki H |
[FK 506, a new immunosuppressant produced by a Streptomyces]. |
1991 |
Nippon Rinsho |
pmid:1712403
|
Hultsch T et al. |
Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. |
1991 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:1712484
|
Miyahara H et al. |
Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. |
1991 |
Clin. Immunol. Immunopathol. |
pmid:1712688
|
McAlpine JB et al. |
Revised NMR assignments for rapamycin. |
1991 |
J. Antibiot. |
pmid:1712766
|
Banerji SS et al. |
The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. |
1991 |
Mol. Cell. Biol. |
pmid:1712901
|
Nelson PA et al. |
cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequence. |
1991 |
Gene |
pmid:1722474
|
Chen MF et al. |
The influence of FK-506 on the thymus and spleen in normal C3H/He mice: flow cytometric analysis of lymphocyte subpopulations. |
1991 |
Immunol. Lett. |
pmid:1722778
|
Sakai K et al. |
The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents. |
1991 |
Brain Res. |
pmid:1723023
|
Weaver JL et al. |
Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. |
1991 |
Immunopharmacol Immunotoxicol |
pmid:1723084
|
Burres NS et al. |
Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins. |
1991 |
J. Antibiot. |
pmid:1723403
|
Nielsen JB et al. |
Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. |
1991 |
Biochemistry |
pmid:2043618
|
Ochiai T et al. |
[Immunosuppressive agents--advances of the developmental studies and the mode of action]. |
1991 |
Nippon Rinsho |
pmid:1715926
|
Liu J et al. |
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. |
1991 |
Cell |
pmid:1715244
|
Henderson DJ et al. |
Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. |
1991 |
Immunology |
pmid:1715317
|
DeFranco AL |
Signal transduction. Immunosuppressants at work. |
1991 |
Nature |
pmid:1715515
|
Flanagan WM et al. |
Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. |
1991 |
Nature |
pmid:1715516
|
McWhinnie DL and Morris PJ |
Combination drug therapies for immunosuppression in transplantation. |
1991 |
Ann. Acad. Med. Singap. |
pmid:1724724
|
Pourtier-Manzanedo A et al. |
FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. |
1991 |
Anticancer Drugs |
pmid:1724925
|
Nakahama H et al. |
Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. |
1991 |
J. Cardiovasc. Pharmacol. |
pmid:1725322
|
Romanowski P et al. |
[Synthetic immunomodulators designed on the basis of natural products of microorganisms]. |
1991 |
Postepy Biochem. |
pmid:1725924
|
|
Unmasking immunosuppression. |
1991 |
Lancet |
pmid:1717800
|
Markus PM et al. |
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. |
1991 |
Transplantation |
pmid:1718063
|
Ryu S and Yasunami Y |
The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. |
1991 |
Transplantation |
pmid:1718064
|
Starzl TE et al. |
Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. |
1991 |
Transplantation |
pmid:1718068
|
Lane WS et al. |
Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus. |
1991 |
J. Protein Chem. |
pmid:1718307
|
James DG |
Which immunomodulator? |
1991 |
Br J Clin Pract |
pmid:1718384
|